Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 437

1.

Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma.

Dreno B, Basset-Seguin N, Caro I, Yue H, Schadendorf D.

Oncologist. 2014 Jul 7. pii: theoncologist.2014-0003. [Epub ahead of print]

PMID:
25001266
[PubMed - as supplied by publisher]
2.

Circulating CD4+ T-cells that produce IL-4 or IL-17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of stage IV melanoma patients.

Zelba H, Weide B, Martens A, Derhovanessian E, Kini Bailur J, Kyzirakos C, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Buttner P, Garbe C, Pawelec G.

Clin Cancer Res. 2014 Jun 17. pii: clincanres.1015.2014. [Epub ahead of print]

PMID:
24938524
[PubMed - as supplied by publisher]
3.

Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study.

Livingstone E, Hollestein LM, van Herk-Sukel MP, van de Poll-Franse L, Joosse A, Schilling B, Nijsten T, Schadendorf D, de Vries E.

Cancer Med. 2014 Jun 17. doi: 10.1002/cam4.285. [Epub ahead of print]

PMID:
24935402
[PubMed - as supplied by publisher]
4.

Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multi-centre, prospective and blinded clinical trial on efficacy and safety.

Malvehy J, Hauschild A, Curiel-Lewandrowski C, Mohr P, Hofmann-Wellenhof R, Motley R, Berking C, Grossman D, Paoli J, Loquai C, Olah J, Reinhold U, Wenger H, Dirschka T, Davis S, Henderson C, Rabinovitz H, Welzel J, Schadendorf D, Birgersson U.

Br J Dermatol. 2014 May 19. doi: 10.1111/bjd.13121. [Epub ahead of print]

PMID:
24841846
[PubMed - as supplied by publisher]
5.

Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients.

Zörnig I, Halama N, Lorenzo Bermejo J, Ziegelmeier C, Dickes E, Migdoll A, Kaiser I, Waterboer T, Pawlita M, Grabe N, Ugurel S, Schadendorf D, Falk C, Eichmüller SB, Jäger D.

Int J Cancer. 2014 May 17. doi: 10.1002/ijc.28980. [Epub ahead of print]

PMID:
24839182
[PubMed - as supplied by publisher]
6.

The impact of the immune system on tumor: angiogenesis and vascular remodeling.

Stockmann C, Schadendorf D, Klose R, Helfrich I.

Front Oncol. 2014 Apr 8;4:69. doi: 10.3389/fonc.2014.00069. eCollection 2014. Review.

PMID:
24782982
[PubMed]
Free PMC Article
7.

Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma.

Stoffels I, Müller M, Geisel MH, Leyh J, Pöppel T, Schadendorf D, Klode J.

Eur J Nucl Med Mol Imaging. 2014 Apr 25. [Epub ahead of print]

PMID:
24764035
[PubMed - as supplied by publisher]
8.

The validity of circulating microRNAs in oncology: Five years of challenges and contradictions.

Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC.

Mol Oncol. 2014 Jun;8(4):819-829. doi: 10.1016/j.molonc.2014.02.009. Epub 2014 Mar 6. Review.

PMID:
24656978
[PubMed - as supplied by publisher]
9.

Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance.

Paschen A, Baingo J, Schadendorf D.

Eur J Cell Biol. 2014 Jan-Feb;93(1-2):49-54. doi: 10.1016/j.ejcb.2014.01.009. Epub 2014 Feb 11.

PMID:
24629838
[PubMed - in process]
10.

Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma.

Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Hömig-Hölzel C, Reuten R, Schadow B, Weighardt H, Wenzel D, Helfrich I, Schadendorf D, Bloch W, Bianchi ME, Lugassy C, Barnhill RL, Koch M, Fleischmann BK, Förster I, Kastenmüller W, Kolanus W, Hölzel M, Gaffal E, Tüting T.

Nature. 2014 Mar 6;507(7490):109-13. doi: 10.1038/nature13111. Epub 2014 Feb 26.

PMID:
24572365
[PubMed - indexed for MEDLINE]
11.

Inherited variation in the PARP1 gene and survival from melanoma.

Davies JR, Jewell R, Affleck P, Anic GM, Randerson-Moor J, Ozola A, Egan KM, Elliott F, García-Casado Z, Hansson J, Harland M, Höiom V, Jian G, Jönsson G, Kumar R, Nagore E, Wendt J, Olsson H, Park JY, Patel P, Pjanova D, Puig S, Schadendorf D, Sivaramakrishna Rachakonda P, Snowden H, Stratigos AJ, Bafaloukos D, Ogbah Z, Sucker A, Van den Oord JJ, Van Doorn R, Walker C, Okamoto I, Wolter P, Barrett JH, Timothy Bishop D, Newton-Bishop J.

Int J Cancer. 2014 Feb 18. doi: 10.1002/ijc.28796. [Epub ahead of print]

PMID:
24535833
[PubMed - as supplied by publisher]
12.

Genetic alterations and personalized medicine in melanoma: progress and future prospects.

Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R.

J Natl Cancer Inst. 2014 Feb;106(2):djt435. doi: 10.1093/jnci/djt435. Review.

PMID:
24511108
[PubMed - indexed for MEDLINE]
13.

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, Scheulen M, Jouary T, Negrier S, Vermorken JB, Kaempgen E, Durando X, Schadendorf D, Gurunath RK, Keilholz U.

Ann Oncol. 2014 Mar;25(3):742-6. doi: 10.1093/annonc/mdt585. Epub 2014 Feb 7.

PMID:
24510314
[PubMed - in process]
14.

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild A.

Lancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7.

PMID:
24508103
[PubMed - indexed for MEDLINE]
15.

Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma.

Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U, Wilhelm T, Loquai C, Berking C, Hassel J, Kähler KC, Utikal J, Al Ghazal P, Gutzmer R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schadendorf D; DeCOG.

Ann Oncol. 2014 Mar;25(3):747-53. doi: 10.1093/annonc/mdt587. Epub 2014 Feb 6.

PMID:
24504444
[PubMed - in process]
16.

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.

Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C.

Ann Oncol. 2014 Mar;25(3):700-6. doi: 10.1093/annonc/mdt580. Epub 2014 Feb 6.

PMID:
24504441
[PubMed - in process]
17.

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.

Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, Robert C, Schadendorf D.

Lancet Oncol. 2014 Mar;15(3):297-304. doi: 10.1016/S1470-2045(14)70007-5. Epub 2014 Jan 31.

PMID:
24485879
[PubMed - indexed for MEDLINE]
18.

Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma.

Hassel JC, Amann PM, Schadendorf D, Eichmüller SB, Nagler M, Bazhin AV.

Exp Dermatol. 2013 Nov;22(11):757-9. doi: 10.1111/exd.12236.

PMID:
24433184
[PubMed - in process]
19.

Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.

Vaubel J, Livingstone E, Schadendorf D, Zimmer L.

J Eur Acad Dermatol Venereol. 2014 Jan 15. doi: 10.1111/jdv.12365. [Epub ahead of print]

PMID:
24422792
[PubMed - as supplied by publisher]
20.

Melanoma in 2013: Melanoma--the run of success continues.

Schadendorf D, Hauschild A.

Nat Rev Clin Oncol. 2014 Feb;11(2):75-6. doi: 10.1038/nrclinonc.2013.246. Epub 2014 Jan 14. No abstract available.

PMID:
24419300
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk